content: SECURITIES AND EXCHANGE COMMISSION
                               WASHINGTON, D.C. 20549
  
              --------------------------------------------------------
  
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(D) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
          Date of report (Date of earliest event reported): August 14, 2003
                                                            ---------------
  
                                 CYTOGEN CORPORATION
              --------------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
  
            Delaware                      000-14879                 22-2322400
  ----------------------------    ------------------------     -------------------
  (State or Other Jurisdiction    (Commission File Number)      (I.R.S. Employer
       of Incorporation)                                       Identification No.)
  
  650 College Road East, CN 5308, Suite 3100, Princeton, NJ              08540
  ---------------------------------------------------------          -------------
         (Address of Principal Executive Offices)                      (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  
  <PAGE>
  ITEM 9.  REGULATION FD DISCLOSURE  (INFORMATION  FURNISHED  PURSUANT TO ITEM 12,
  "DISCLOSURE OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION").
  
           On August 14, 2003, Cytogen  Corporation (the "Company")  announced its
  financial  results for the  quarter  ended June 30,  2003.  The full text of the
  press release issued in connection with the  announcement is attached as Exhibit
  99.1 to this Current Report on Form 8-K.
  
           In accordance with the procedural  guidance in SEC Release Nos. 33-8216
  and 34-47583,  the information in this Form 8-K and the Exhibit  attached hereto
  is being furnished  under "Item 9.  Regulation FD Disclosure"  rather than under
  "Item 12.  Disclosure of Results of Operations  and  Financial  Condition."  The
  information  shall not be deemed  "filed"  for  purposes  of  Section  18 of the
  Securities  Exchange Act of 1934, as amended (the "Exchange  Act"), or otherwise
  subject to the liabilities of that section,  nor shall it be deemed incorporated
  by reference in any filing under the Securities Act of 1933, as amended,  or the
  Exchange  Act,  except as  expressly  set forth by specific  reference in such a
  filing.
  
  
  
  <PAGE>
                                     SIGNATURES
  
  
  
           Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
  the  Registrant  has duly caused this current report on Form 8-K to be signed on
  its behalf by the undersigned hereunto duly authorized.
  
                                        CYTOGEN CORPORATION
  
  
  
                                        By:  /s/ Michael D. Becker
                                             -----------------------------
                                             Michael D. Becker
                                             President and Chief Executive
                                             Officer
  
  Dated:   August 14, 2003
  
  
  
  <PAGE>
  
  
                                    EXHIBIT INDEX
  
  
                        Exhibit No.       Description
                        -----------       -----------
  
                            99.1          Press release dated August14, 2003.
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "form8k081403.txt", "description": "FORM 8-K DATED 08/14/03", "secsgml_size_bytes": 3522}]
metadata_filer: {"company-data": {"conformed-name": "CYTOGEN CORP", "cik": "0000725058", "assigned-sic": "2835", "irs-number": "222322400", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-14879", "film-number": "03847833"}, "business-address": {"street1": "600 COLLEGE RD EAST CN 5308", "city": "PRINCETON", "state": "NJ", "zip": "08540", "phone": "6099878200"}, "mail-address": {"street1": "600 COLLEGE RD EAST CN 5308", "street2": "600 COLLEGE RD EAST CN 5308", "city": "PRINCETON", "state": "NJ", "zip": "08540"}}
text: SECURITIES AND EXCHANGE COMMISSION
                               WASHINGTON, D.C. 20549
  
              --------------------------------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(D) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
          Date of report (Date of earliest event reported): August 14, 2003
                                                            ---------------
  
                                 CYTOGEN CORPORATION
              --------------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
            Delaware                      000-14879                 22-2322400
  ----------------------------    ------------------------     -------------------
  (State or Other Jurisdiction    (Commission File Number)      (I.R.S. Employer
       of Incorporation)                                       Identification No.)
  
  650 College Road East, CN 5308, Suite 3100, Princeton, NJ              08540
  ---------------------------------------------------------          -------------
         (Address of Principal Executive Offices)                      (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  ITEM 9.  REGULATION FD DISCLOSURE  (INFORMATION  FURNISHED  PURSUANT TO ITEM 12,
  "DISCLOSURE OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION").
  
           On August 14, 2003, Cytogen  Corporation (the "Company")  announced its
  financial  results for the  quarter  ended June 30,  2003.  The full text of the
  press release issued in connection with the  announcement is attached as Exhibit
  99.1 to this Current Report on Form 8-K.
  
           In accordance with the procedural  guidance in SEC Release Nos. 33-8216
  and 34-47583,  the information in this Form 8-K and the Exhibit  attached hereto
  is being furnished  under "Item 9.  Regulation FD Disclosure"  rather than under
  "Item 12.  Disclosure of Results of Operations  and  Financial  Condition."  The
  information  shall not be deemed  "filed"  for  purposes  of  Section  18 of the
  Securities  Exchange Act of 1934, as amended (the "Exchange  Act"), or otherwise
  subject to the liabilities of that section,  nor shall it be deemed incorporated
  by reference in any filing under the Securities Act of 1933, as amended,  or the
  Exchange  Act,  except as  expressly  set forth by specific  reference in such a
  filing.
  SIGNATURES
  
           Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
  the  Registrant  has duly caused this current report on Form 8-K to be signed on
  its behalf by the undersigned hereunto duly authorized.
  
                                        CYTOGEN CORPORATION
  
                                        By:  /s/ Michael D. Becker
                                             -----------------------------
                                             Michael D. Becker
                                             President and Chief Executive
                                             Officer
  
  Dated:   August 14, 2003
  EXHIBIT INDEX
  
                        Exhibit No.       Description
                        -----------       -----------
  
                            99.1          Press release dated August14, 2003.